Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trialFeng Bi, Weijian Guo, Chuan Jin et al.|Journal of Hematology & Oncology|2024Cited by 8